Ocular Immunology and Inflammation · 2010 · 99 citations · 25 references
MedicineOphthalmologyPharmacotherapyImmunotherapyOcular DiseaseOcular ImmunologyAutoimmune Eye DiseaseAutoimmune Ocular DiseaseOcular InflammationAnti-inflammatory Eye MedicationsAnti-inflammatory Ocular TherapyClinical Outcome MeasurementImmunosuppressive CompoundsOcular Autoimmunity
PURPOSE: To describe the clinical outcome of refractory ocular Behçet disease with adalimumab therapy. METHOD: Retrospective review of records. RESULTS: Twenty-one eyes of 11 male patients with ocular Behçet disease received adalimumab therapy. Of the 21 eyes, 17 had improvement of visual acuity by more than 3 lines after the average follow-up of 10.8 months. Ten out of 11 patients showed complete resolution of inflammation by 4 weeks. The dosages of corticosteroids and immunosuppressive drugs were reduced in most of the patients and stopped altogether in 3 and 6 patients, respectively. One patient on infliximab showed improvement of inflammation after switching over to adalimumab. No serious side effects were observed in any of the patients. CONCLUSION: Adalimumab appears to be effective in Behçet disease. It has been shown to improve visual acuity and also to have a corticosteroid and immunosuppressive sparing effect. It can induce and maintain sustained remission of the disease.
25
Criteria for diagnosis of Behçet's disease
B Weichsler, Fereydoun Davatchi, Thomas Lehner et al. · The Lancet · 1990 · 3.1K citations
Désirée van der Heijde, Alan Kivitz, Michael Schiff et al. · Arthritis & Rheumatism · 2006 · 878 citations
Michael J. Hogan, Samuel J. Kimura, Phillips Thygeson · American Journal of Ophthalmology · 1959 · 527 citations